This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Carcinoma in situ of breast유방의 제자리암 (유방제자리암)

📋 Contents and key points
A. Classification codesICD-10: D05 | D05.0 Lobular carcinoma in situ (LCIS) | D05.1 Intraductal carcinoma in situ (DCIS) | D05.8 Other carcinoma in situ of breast | D05.9 Carcinoma in situ of breast, unspecified | Special Copayment Reduction V193 (5% copayment, for 5 years from the registration date)
B. SynonymsDuctal carcinoma in situ (DCIS), carcinoma in situ of the breast ducts, lobular carcinoma in situ (LCIS), breast intraepithelial carcinoma, Paget's disease of nipple, noninvasive breast cancer, high-grade dysplasia of the breast ducts, comedo DCIS
C. Adult onsetVery high — DCIS mainly in people in their 40s–70s; with the spread of mammography screening, most are detected on screening at age 40 or older; LCIS is relatively common in premenopausal women (aged 35–55)
Contents 1. History · 2. Causes · 3. Genetics · 4. Epidemiology · 5. Pathophysiology · 6. Symptoms · 7. Signs · 8. Screening · 9. Diagnosis · 10. Treatment · 11. Prognosis · 12. Prevention · 13. References
1. History summaryThe spread of mammography (1970s–80s) led to a surge in DCIS detection; development of the Van Nuys Prognostic Index (1995) established the basis for individualized treatment.
2. Causes summaryRadiation exposure; hormone therapy (estrogen + progestin); BRCA1/2 mutations; family history; previous atypical hyperplasia; obesity and alcohol consumption.
3. Genetics summaryBRCA1/2, ATM, PALB2 (hereditary); PIK3CA, TP53, CDH1, CCND1 (somatic); HER2 amplification (high nuclear grade DCIS); ER/PR status; molecular subtypes.
4. Epidemiology summaryDCIS is about 25% of breast cancers detected by mammography screening; of about 27,000 new breast cancer cases per year in Korea, about 5,000 are DCIS; incidence is increasing.
5. Pathophysiology summaryNormal breast duct epithelium → atypical proliferation → DCIS (confined within the duct) → invasive cancer when the basement membrane is breached; distinct ER+ low-grade and HER2+ high-grade pathways.
6. Symptoms summaryMostly asymptomatic (incidental finding on mammography); some present with a palpable mass, nipple discharge, or Paget's disease of the nipple.
7. Signs summaryMicrocalcifications on mammography (comedo type); non-mass linear enhancement on MRI; BI-RADS 4-5; eczema-like nipple lesion in Paget's disease of the nipple.
8. Screening summaryKorean national breast cancer screening: mammography every 2 years from age 40; BRCA high-risk group: annual MRI + mammography from age 25-30.
9. Diagnosis summaryStereotactic core biopsy; vacuum-assisted biopsy (VAB); MRI-guided biopsy; ER/PR/HER2/Ki-67; Oncotype DX DCIS score; Van Nuys index.
10. Treatment summaryBreast-conserving surgery + radiation (NSABP B-17/B-24); omission of radiation in low-risk DCIS (RTOG 9804/ECOG 5194); endocrine therapy (ER+); radiation decision with Oncotype DCIS.
11. Prognosis summaryLocal recurrence about 10-15% at 5-10 years after breast conservation + radiation; 1-2% after mastectomy; extremely low risk of systemic metastasis; survival much better than invasive cancer.
12. Prevention summaryParticipation in regular mammography; BRCA testing and prophylactic surgery (high-risk group); tamoxifen (chemoprevention); limiting alcohol; maintaining a healthy weight.

1. History

The history of carcinoma in situ of the breast (D05) is inseparably linked to advances in breast imaging technology. Lobular carcinoma in situ (LCIS) was first described in 1941 by Foote and Stewart; it was initially regarded as a precursor lesion of invasive breast cancer and was later redefined as a risk indicator for bilateral breast cancer. Ductal carcinoma in situ (DCIS) has been known since the early 20th century but was treated as a very rare clinical lesion.

The clinical introduction and spread of mammography in the 1960s–70s was the decisive turning point in the history of DCIS. Through the US HIP (Health Insurance Plan) study begun in 1963 and numerous subsequent randomized controlled trials, it was established that mammography screening reduces breast cancer mortality. In the process, the detection rate of DCIS increased dramatically, and in the United States DCIS came to account for about 25% of breast cancers detected by mammography screening. Considering that DCIS was less than 1% of all breast cancers in the pre-screening era, this is a paradigm shift.

The history of DCIS treatment has evolved in the direction of moving away from overtreatment. Until the 1980s, total mastectomy was the standard, but the NSABP B-17 trial (results published in 1993) showed that breast-conserving surgery + radiation is equivalent to total mastectomy in survival. The USC/Van Nuys Prognostic Index (VNPI), developed by Melvin Silverstein in 1995, scored 5 factors, including tumor size, margin width, nuclear grade, and age, providing a basis for individualizing treatment. Recently, molecularly based prediction of the need for radiation using the Oncotype DX DCIS score and clinical trials studying omission of radiation in very low-risk DCIS (COMET, LORIS, LORD) are underway.

2. Causes

The causes of DCIS/LCIS share risk factors similar to those of invasive breast cancer. Hormone-related factors: combined exogenous estrogen + progestin hormone replacement therapy increases the risk of DCIS about 1.5-2-fold. Earlier age at menarche or later menopause lengthens the duration of estrogen exposure and increases risk. Late age at first birth, nulliparity, and a short duration of breastfeeding are also risk factors. Radiation exposure: a history of radiation therapy to the chest (mantle radiation for Hodgkin lymphoma) markedly increases the risk of DCIS and invasive breast cancer. Family history and heredity: a history of breast cancer in a first-degree relative (mother, sister, daughter) increases the risk of DCIS 1.5-3-fold. Germline BRCA1 or BRCA2 mutations raise the lifetime risk of breast cancer (including DCIS) to as much as 50-80%. Germline ATM, PALB2, and CHEK2 mutations also increase breast cancer risk 2-3-fold. Lifestyle factors: obesity (BMI >30), drinking 1-2 or more drinks a day, and physical inactivity are risk factors for breast cancer in general. Previous atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH) are high-risk precursor lesions that increase the risk of DCIS/invasive breast cancer 4-5-fold.

3. Genetics

Hereditary DCIS: BRCA1 mutation-associated DCIS mainly presents as high nuclear grade, estrogen receptor-negative (ER-), HER2-negative (HER2-) triple-negative or basal-like molecular subtypes. BRCA2 mutation-associated DCIS has a relatively high frequency of ER+ and low nuclear grade. ATM and PALB2 mutations also increase breast cancer risk, but to a lower level than BRCA1/2. Somatic genetic changes: PIK3CA mutation (the most common single variant in ER+ DCIS); TP53 mutation (frequent in high nuclear grade, ER- DCIS); CDH1 mutation (specific to LCIS and invasive lobular carcinoma); CCND1 (11q13) amplification is common in high nuclear grade DCIS. HER2 (ERBB2) amplification: HER2 amplification occurs in about 40-60% of high nuclear grade comedo-type DCIS and is a risk factor for invasive transformation. DCIS molecular subtypes: classified as luminal A/B (ER+, low/intermediate grade), HER2-overexpressing (ER-, HER2+), and triple-negative (ER-, PR-, HER2-), and the risk of local recurrence and invasive progression differs by molecular subtype. The Oncotype DX DCIS Score quantifies the expression of 7 genes (Ki67, STK15, Survivin, CCNB1, MYBL2, PR, GSTM1) to predict the risk of local recurrence.

4. General epidemiology

DCIS has increased markedly in Korea along with the rising incidence of breast cancer. Annual new cases of breast cancer in Korea are about 27,000-28,000 (as of 2022), of which noninvasive breast cancer, including DCIS, accounts for about 5,000, or about 18-20% of the total. In the United States, DCIS accounts for about 25% of breast cancers detected by mammography screening, with more than about 50,000 new diagnoses per year.

The incidence of DCIS has increased dramatically since the introduction of mammography screening (about 7-10-fold in the United States compared with 1980, before screening). High nuclear grade DCIS in particular is increasing rapidly. In Korea, as participation in national breast cancer screening (mammography every 2 years from age 40) increases, the DCIS detection rate is also rising. LCIS is rarer than DCIS, occurs mainly in premenopausal women (aged 35-55), and has an incidence of about 3-4 per 100,000 population. About 80-85% of DCIS occurs in women, but it also occurs rarely in men (about 10% of all male breast cancers).

5. Pathophysiology

Two main pathways are proposed for the development of DCIS. Low-grade ER+ pathway: normal breast duct epithelium → usual ductal hyperplasia (UDH) → atypical ductal hyperplasia (ADH) → low nuclear grade DCIS → low-grade invasive breast cancer. This pathway mainly progresses to the ER+, luminal A molecular subtype and advances slowly over years to decades. High-grade ER- or HER2+ pathway: normal breast duct → high nuclear grade DCIS (with comedo necrosis) → high-grade invasive breast cancer. This pathway is associated with HER2 amplification and TP53 mutation and tends to progress more rapidly.

Basement membrane degradation is central to the transition from DCIS to invasive cancer. DCIS cells are separated from the stroma by the myoepithelial cell layer and the basement membrane, and progression to invasive cancer occurs when these layers are destroyed. MMPs (matrix metalloproteinases), VEGF, and growth factors are involved in this process. Importantly, DCIS does not necessarily progress to invasive cancer; in long-term follow-up studies, about 14-53% of untreated DCIS progressed to invasive cancer (in the form of local recurrence). This is the basis of the controversy over overdiagnosis and overtreatment.

6. Symptoms

The majority of DCIS (about 80-90%) is asymptomatic and is found incidentally on mammography screening. This is the most clinically important characteristic of DCIS. Before mammography screening was introduced, most DCIS was diagnosed only after symptoms developed.

When symptoms are present: Palpable mass: in larger DCIS or high nuclear grade comedo-type DCIS, a hard lump may be palpable in the breast. Nipple discharge: DCIS is suspected when bloody or serosanguineous nipple discharge arises from a single ipsilateral duct. Nipple discharge occurs in about 5-12% of all breast cancers. Paget's disease of the nipple: eczema-like changes, erythema, skin peeling, and itching of the skin of the nipple and areola appear. Underlying DCIS or invasive cancer accompanies 85-100% of cases of Paget's disease of the nipple. Breast pain: pain due to DCIS itself is rare. Rarely, skin dimpling of the breast or nipple retraction may be present.

7. Signs

Mammographic findings: about 70-80% of DCIS is detected on mammography. The most common finding is clustered microcalcifications, and microcalcifications with linear, branching, or irregular distribution are particularly specific for DCIS. Comedo-type DCIS is characterized by large, coarse, heterogeneous calcifications. Noncalcified DCIS may appear on mammography as architectural distortion or asymmetric density. Classification as BI-RADS 4 or 5 requires tissue biopsy.

Breast MRI findings: MRI is useful for determining the extent of DCIS found on mammography, checking for multifocal or bilateral disease, and evaluating for the presence of an invasive component. Non-mass linear or segmental enhancement is the characteristic MRI finding of DCIS. Breast MRI is also used as a screening tool for high-risk BRCA carriers. Ultrasound findings: ultrasound is used as a complement to mammography, but because its sensitivity for DCIS is lower than mammography, it is not used as the main screening tool. It is useful for evaluating duct dilation when nipple discharge is present.

8. Screening

Korean national breast cancer screening: free mammography screening is provided every 2 years to women aged 40 and older. In national cancer screening, a radiologist interprets the images, and abnormal findings are linked to additional tests (compression mammography, ultrasound, MRI, biopsy). Meta-analyses have confirmed that mammography screening reduces breast cancer mortality by about 20-40%.

Screening of hereditary high-risk groups: for BRCA1 or BRCA2 variant carriers, those with a BRCA carrier among first-degree relatives, those with a history of radiation therapy at a young age (chest radiation at age 10-30), and those with a lifetime breast cancer risk >20-25%, annual breast MRI + mammography is performed from age 25-30. In high-risk women with a history of LCIS or ADH/ALH, annual screening (mammography ± MRI) and risk-reducing medication (tamoxifen, raloxifene) are considered. For BRCA carriers, risk-reducing mastectomy can be discussed after genetic counseling.

9. Diagnosis

The final diagnosis of DCIS is confirmed by histopathological examination. Stereotactic core needle biopsy: the most common diagnostic method, performed on calcified lesions under mammographic guidance. A 14-gauge or larger core biopsy or vacuum-assisted biopsy (VAB) is used. VAB obtains more tissue and reduces underestimation. MRI-guided biopsy: MRI-guided biopsy is performed when a lesion is not seen on mammography or ultrasound but is suspicious on MRI.

Histopathology: nuclear grade of DCIS (low, intermediate, high grade), presence of comedo necrosis, lesion size, distance to the margin, and architectural pattern (solid, cribriform, papillary, micropapillary, comedo). Immunohistochemistry: ER, PR (estrogen and progestin receptors), HER2 (3+ or FISH positive), Ki-67 (proliferation index). Oncotype DX DCIS Score: quantifies the expression of 7 genes, expressed as a score of 0-100; the score predicts the 10-year risk of local recurrence in the excision-alone group (score ≤38: low risk). It was validated with tissue from the E5194 trial. USC/Van Nuys Prognostic Index (USC/VNPI): scores 5 factors—size, margin width, nuclear grade, age, and comedo necrosis—at 1-3 points each (total 5-15 points) and is used as a guideline for treatment selection.

10. Treatment

The core principle of DCIS treatment is to prevent progression to invasive cancer through local control. Because the risk of systemic metastasis is extremely low, the need for systemic therapy is limited.

Breast-conserving surgery (BCT) + radiation therapy (RT): NSABP B-17 (1993) and EORTC 10853 (2000) confirmed that RT after BCT reduces local recurrence by about 50% compared with BCT alone. In NSABP B-24 (1999), adding tamoxifen to RT showed additional reduction in recurrence. Low-risk DCIS with omission of radiation: in ECOG-ACRIN E5194 (ECOG 5194) and RTOG 9804, when low-risk clinicopathological criteria (small lesion, low/intermediate nuclear grade, margin ≥3mm) were met, 15-year local recurrence rates after omission of radiation differed somewhat, at 16-26% (E5194) and 7% (RTOG 9804 observation arm). There is evidence supporting omission of radiation in the Oncotype DX DCIS low-risk group (score ≤38). Endocrine therapy: in ER+ DCIS, tamoxifen (20mg/day, 5 years, premenopausal) reduces ipsilateral DCIS/invasive cancer recurrence by about 30-50% (NSABP B-24). After menopause, aromatase inhibitors (anastrozole, letrozole) show effects similar to or better than tamoxifen (NSABP B-35). Total mastectomy: considered for extensive or multifocal DCIS, BRCA carriers, repeated recurrence, or when clear margins cannot be obtained.

11. Prognosis

DCIS has a very favorable prognosis overall. 10-year breast cancer-specific mortality: at 10-20 years of follow-up after a DCIS diagnosis, breast cancer mortality is only 3-4%, nearly the same as in the general population. Local recurrence rate after breast-conserving surgery + radiation: about 5-8% at 5 years and about 10-15% at 10 years. About 50% of recurrences are invasive cancer, and with appropriate treatment of recurrence, survival is maintained. Recurrence rate after total mastectomy: 1-2% (extremely low). Poor prognostic factors: high nuclear grade, comedo necrosis, positive margins, HER2 amplification, a high Oncotype DCIS score, and young age (<40 years). LCIS: traditionally interpreted as a risk indicator for bilateral breast cancer; after a diagnosis of classic LCIS, the annual risk of invasive breast cancer is about 1-1.5%. Pleomorphic LCIS shows a higher risk of invasive transformation. Regular follow-up after treatment: clinical examination every 6-12 months for the first 5 years, then annual clinical examination + annual mammography.

12. Prevention

Participation in regular mammography screening: actively participate in Korean national breast cancer screening (every 2 years from age 40) to detect DCIS early. Early detection of DCIS through screening mammography prevents progression to invasive cancer. Genetic counseling and BRCA testing: when there is a strong family history of breast cancer or a family member diagnosed with breast cancer at a young age, receive genetic counseling and undergo BRCA genetic testing if needed. In BRCA carriers, risk-reducing mastectomy reduces the risk of developing breast cancer by more than 90%.

Chemoprevention: in high-risk groups such as atypical ductal hyperplasia (ADH), LCIS, and BRCA carriers, tamoxifen (20mg/day, 5 years) or raloxifene reduces the risk of invasive breast cancer by about 30-50%. In postmenopausal women, aromatase inhibitors (anastrozole, exemestane) are also used for prevention. Lifestyle improvement: maintaining a normal weight (BMI 18.5-25), regular physical activity (150 minutes or more of moderate aerobic exercise per week), minimizing alcohol (1 drink or less per day), breastfeeding. Caution with hormone replacement therapy: avoid long-term use of combined estrogen + progestin therapy for control of menopausal symptoms, and if needed, use it only for the shortest period.


13. References

  1. Silverstein MJ, et al. Introduction, evolution, and application of the Van Nuys Prognostic Index in DCIS. In: Silverstein MJ, ed. Ductal Carcinoma In Situ of the Breast. 2nd ed. Lippincott Williams & Wilkins; 2002:459-473.
  2. Fisher B, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16(2):441-452.
  3. Fisher B, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993-2000.
  4. Solin LJ, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701-710.
  5. Wapnir IL, et al. Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study. npj Breast Cancer. 2024;10:21.
  6. McCormick B, et al. RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33(7):709-715.
  7. Margolese RG, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35). Lancet. 2016;387(10021):849-856.
  8. National Cancer Center. 2024 Korean Clinical Practice Guidelines for Breast Cancer. National Cancer Center, 2024.
  9. Gradishar WJ, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2024. National Comprehensive Cancer Network, 2024.
  10. Korean Statistical Information Service. 2022 National Cancer Statistics. Korea Central Cancer Registry; 2023.